Patent SG-11201903326R-A (SG)
Title: Liposomal formulation for use in the treatment of cancer
Inventor: WESSELS PETER
IPC: A61K9/127
Filed: 2017-10-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111H1111011101100111111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/078064 Al 03 May 2018 (03.05.2018) W I P0 I P C T (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/519 (2006.01) A61K 9/127 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61P 35/00 (2006.01) (21) International Application Number: Published: PCT/EP2017/077538 — with international search report (Art. 21(3)) (22) International Filing Date: 27 October 2017 (27.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16306415.7 28 October 2016 (28.10.2016) EP (71) Applicants: LES LABORATOIRES SERVIER [FR/FR]; 35 rue de Verdun, 92284 SURESNES (FR). NO- VARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: WESSELS, Peter; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). TIEMESSEN, Henricus; c/ o Novartis Pharma AG, Postfach, 4002 Basel (CH). DE MARCO, Paolo; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). LARABI, Malika; c/o HIQ Consulting AG, Aeschenvorstadt 52, 6051 BASEL (CH). SCHIEDEL, Christiane; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). GURINA, Marina; c/o KELLY SERVICES AG, Grenzacherweg 78, 4125 Riehen (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional available): ARIPO (BW, GH, protection GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 i i. (54) Title: LIPOSOMAL FORMULATION FOR USE IN THE TREATMENT OF CANCER V::+ c: : :: , (57) : The invention relates to a pharmaceutical liposomal composition comprising 2- f[5- {3-chloro-2-methyl-442-(4- Pt methylpiperazin-l-ypethoxy]phenyll -6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yfloxyl -3-(2- { [2-(2-methoxyphenyl)pyrimidin-4- C yflmethoxylphenyl) propanoic acid, referred to herein as 'Compound A', or a pharmaceutically acceptable salt thereof. More specifi- cally the invention relates to a liposomal vehicle, an organic concentratecompositioncomprising Compound A, and a pharmaceutical cie , I composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such 1:::: ) compositions for the treatment of cancer. 'Compound A' as used herein includes all enantiomers, diastereoisomers, and atropisomers N thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof. C